Introduction
============

Kinesin Family Member 3A (KIF3A) is regarded as a motor protein, which is associated with the intraflagellar transport system of primary cilia and maintenance of ciliogenesis ([@b1-br-0-0-1061],[@b2-br-0-0-1061]). In addition, KIF3A plays a role in primary cilia formation and in centriole cohesion and subdistal appendage organization and function ([@b3-br-0-0-1061]). In 2013, Barakat *et al* reported that KIF3A is necessary for the initiation and maintenance of medulloblastoma for the first time ([@b4-br-0-0-1061]). Liu *et al* also proved that KIF3A plays a critical role in prostate cancer ([@b5-br-0-0-1061]). Recently, Kim *et al* found that KIF3A is a class of tumor suppressors in non-small cell lung cancer ([@b6-br-0-0-1061]).

Previous findings showed that primary cilia decreased in breast cancer ([@b7-br-0-0-1061]--[@b9-br-0-0-1061]). In addition, the disrupted expression of KIF3A leads to ablate ciliogenesis and tumorigenesis in glioblastoma ([@b10-br-0-0-1061]).

Thus, we hypothesized that KIF3A may affect the formation and/or pathological change of primary cilia in breast cancer, and subsequently on tumor progression. Therefore, the aim of this study was to explore the possible relationship of KIF3A and breast cancer progression, and by analyzing such a relationship to explore its possible clinical usage.

Materials and methods
=====================

### Study subjects

The samples of tissue microarrays (Xinchao Biotechnology Company, Shanghai, China) were collected from 140 tissues of mammary carcinoma patients and 90 adjacent para-carcinoma tissues (2 cm from the tumor tissues) as controls. Within the total of 230 cases, 70 self-contrast tissues were included. A long-term follow-up was carried out to all the patients as long as 14 years, while the survival rate was measured up to 2013 and 2014, respectively. Details of the clinicopathological parameters are presented in the results.

### Immunohistochemical detection of KIF3A

The expression level of KIF3A was detected by immunohistochemical staining, performed according to the instructions of the SP kit ZSGB-BIO, Beijing, China). The antibody for KIF3A was rabbit polyclonal anti-KIF3A (1:800; cat. no. K3513; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Results of the staining were evaluated separately by three pathologists under double-blind conditions and scored by the intensity of positive, the positive rates and final score (score of positive rates multiplied by score of intensity of positive). Detailed scoring system and criteria are presented in [Table I](#tI-br-0-0-1061){ref-type="table"}.

### Statistical analysis

The Chi-square test was performed to analyze the differences in the expression of KIF3A between the 140 tumor tissues and 90 adjacent para-carcinoma tissues, as well as the correlations of clinicopathological parameters of corresponding patients. Kaplan-Meier survival values were calculated to evaluate the connection between the expression level of KIF3A and the survival rate. Survival between the groups was compared using the log-rank test. Statistical significance was set at P\<0.05, while P\<0.001 indicated extremely statistically significant. The software used was SPSS Version 21.0 (SPSS, Inc., Chicago, IL, USA).

Results
=======

### Expression pattern of KIF3A in breast cancer

Tissue microarrays were used to detect the expression status of KIF3A in 230 cases. The intensity of positive, the positive rate and the final score were measured for further statistical analysis, respectively ([Tables II](#tII-br-0-0-1061){ref-type="table"} and [III](#tIII-br-0-0-1061){ref-type="table"}).

The Chi-square test on the scores of intensity of positive, positive rate and the final score, showed KIF3A expression levels were significantly higher in 140 breast cancer tissues than those in adjacent para-carcinoma tissues (P\<0.01). The same significant difference was also observed in the 70 self-contrast cases ([Fig. 1](#f1-br-0-0-1061){ref-type="fig"}).

### Expression of KIF3A and clinicopathological parameters

Currently used clinical pathological parameters of the 230 breast cancer cases in this study are shown in [Table IV](#tIV-br-0-0-1061){ref-type="table"}. The average age of the patients was 53 (from 31 to 83 years). Pathological grade was categorized as grade I, II and III.

According to the intensity of positive, the positive rate and the final score, the expression pattern of KIF3A and the clinicopathological parameters in the 140 cases were evaluated, respectively ([Tables V](#tV-br-0-0-1061){ref-type="table"}--[VII](#tVII-br-0-0-1061){ref-type="table"}).

In terms of the intensity of positive in the 140 breast cancer patients, the statistical analysis revealed that the higher level expression of KIF3A was correlated with the status of lymph node metastasis, pathological grade, and the expression of androgen receptor (AR) and epidermal growth factor receptor (EGFR). In addition, the Chi-square test on both the positive rate and final score indicated that a higher level of expression of KIF3A was correlated with higher pathology grade and the expression of estrogen receptor (ER) and Ki-67.

### Expression of KIF3A and prognosis in breast cancer patients

Kaplan-Meier analysis of the intensity of positive, the positive rate and the final score was applied to explore the association between KIF3A expression and the survival rate of 140 patients followed up to the year of 2013 and 2014.

For the cases followed up to 2013, grouped as KIF3A positive (+, ++, +++) and negative (−), a statistical significance was only identified between KIF3A expression and survival rate (P=0.047) when evaluated by intensity of positive ([Fig. 2](#f2-br-0-0-1061){ref-type="fig"} and [Table VIII](#tVIII-br-0-0-1061){ref-type="table"}).

For the cases up to 2014, positive (++) patients showed an improved prognosis (P=0.045; [Fig.2](#f2-br-0-0-1061){ref-type="fig"} and [Table IX](#tIX-br-0-0-1061){ref-type="table"}).

Discussion
==========

KIF3 is a heterotrimeric complex that consists of KIF3A, KIF3B, and kinesis-associated protein 3 (KAP3) ([@b11-br-0-0-1061]), the complex is considered as microtubule (MT)-dependent molecular motors that function in intracellular transport ([@b12-br-0-0-1061]), which is expressed ubiquitously. KIF3A is involved in the anterograde transport of membranous organelles, distinct from synaptic vesicle precursors and from vesicles, also required for ciliary basal feet formation and MT anchoring to mother centriole ([@b3-br-0-0-1061]). Thus, KIF3A plays an important role in the procedure of ciliogenesis.

KIF3A was also reported to be associated with certain pathological processes. It has been reported that KIF3A is involved in forming defective bone formation and osteopenia ([@b13-br-0-0-1061]) and defective osteoblastic differentiation in dental mesenchymal stem/precursor cells ([@b14-br-0-0-1061]). Since 2013, the expression and function of KIF3A has been regarded as statistically significantly and correlated with several tumors such as glioblastoma, prostate cancer and medulloblastoma ([@b4-br-0-0-1061],[@b5-br-0-0-1061],[@b10-br-0-0-1061]). It has been demonstrated that disruption of the expression of KIF3A leads to ablate ciliogenesis and tumorigenesis in glioblastoma ([@b10-br-0-0-1061]).

Since KIF3A is associated with ciliogenesis and primary cilia decrease in breast cancer ([@b7-br-0-0-1061]--[@b9-br-0-0-1061]), identifying the association of KIF3A and breast cancer progression is of great importance. Our results showed that the expression of KIF3A is extremely higher in breast cancer tissues than that in para-carcinoma tissues, and this difference was confirmed by the 70 self-contrast tissues. Barakat *et al* have reported that the difference of KIF3A expression has the same relationship with primary cilia ([@b4-br-0-0-1061]). Based on our results, KIF3A is associated with progression of breast cancer.

No reports have previously focused on the relationship between KIF3A expression and breast cancer progression. Thus, we statistically analyzed the clinical mainstream clinicopathological parameters. Our data suggested that the high expression of KIF3A was correlated with clinical diagnosis and prognosis including: lymph node metastasis, pathological grade, AR, ER, EGFR and Ki-67. In clinic, these parameters are not sufficient for the accurate diagnosis and prognosis of breast cancer, particularly triple negative breast cancer. Thus, it is imperative to add new parameters for breast cancer, and according to findings of the present study, we suggest that KIF3A be a new candidate parameter of breast cancer.

The expression of KIF3A was associated with survival in breast cancer patients up to 2013. Furthermore, Kaplan-Meier survival curves showed positive (++) KIF3A combined with longer survival according to the data of 2014. Based on the statistical analysis on the relationship with existing parameters and KIF3A, the high expression of KIF3A is associated with ER, AR, EGFR and Ki-67. Concerning the associated parameters, ER, AR and Ki-67 are regarded as a reference index to evaluate prognosis status. Of these, ER and AR are selected from hormonic effect and Ki-67 is based on cell cycle, while KIF3A is associated with the pathological change of primary cilia. Therefore, we suggest KIF3A can be used as a new parameter to evaluate prognosis in a novel way.

In conclusion, the high expression of KIF3A is associated with the progression of breast cancer. Furthermore, its high expression is also associated with breast cancer prognosis parameters ER, AR, EGFR and Ki-67. These results indicate that KIF3A can be used as a diagnostic indicator, and also as a new prognosis parameter to evaluate breast cancer considering its particular function on the pathological change of primary cilia.
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![IHC of KIF3A in human breast cancer and para-carcinoma tissues microarrays. IHC of KIF3A in (A) human breast cancer and (B) para-carcinoma tissues (magnification, ×400). IHC, immunological histological chemistry; KIF3A, Kinesin Family Member 3A.](br-08-04-0343-g00){#f1-br-0-0-1061}

![Kaplan-Meier survival curves of KIF3A expression and survival rate of 140 breast cancer cases in 2013. (A) Kaplan-Meier survival analysis basing on KIF3A intensity of positive (P=0.047). (B) Kaplan-Meier survival analysis basing on KIF3A-positive rate (P=0.068). (C) Kaplan-Meier survival analysis basing on KIF3A final score (P=0.635). (D) Kaplan-Meier survival of the intensity of positive (P=0.045). (E) Kaplan-Meier survival of the positive rate (P=0.217). (F) Kaplan-Meier survival of the final score (P=0.223). KIF3A, Kinesin Family Member 3A.](br-08-04-0343-g01){#f2-br-0-0-1061}

###### 

Methods of scoring system and criteria for immunohistochemical results.

  Score                   Criteria
  ----------------------- ---------------------------------------------------
  Intensity of positive   
    0                     Negative (−)
    1                     Weakly positive (+)
    2                     Medium positive (++)
    3                     Strong positive (+++)
  Positive rate           
    0                     No or 0% nuclear and cytoplasm staining (−)
    1                     \<15% or occasional nuclear staining (1--15%) (+)
    2                     \>15 to 75% clear positive nuclear staining (++)
    3                     \>75% positive staining (+++)
  Final score             
    0                     Total score 0--2
    1                     Total score 3--5
    2                     Total score 6--8
    3                     Total score 9--11

###### 

Expression level of KIF3A in 140 cases breast cancer patients and 90 para-carcinoma tissues.

                          Score                           
  ----------------------- ------- ---- ----- ----- ------ ------------------------------------------------------
  Intensity of positive                                   \<0.001^[a](#tfn1-br-0-0-1061){ref-type="table-fn"}^
    Cancer                  4     22   56    58    140    
    Formal                24      31   31      4     90   
    No.                   28      53   87    62    230    
  Positive rate                                           \<0.001^[a](#tfn1-br-0-0-1061){ref-type="table-fn"}^
    Cancer                  8     21   66    45    140    
    Formal                23      16   46      5     90   
    No.                   31      37   112   50    230    
  Final score                                             \<0.001^[a](#tfn1-br-0-0-1061){ref-type="table-fn"}^
    Cancer                  8     32   52    48    140    
    Formal                25      30   31      4     90   
    No.                   33      62   83    52    230    

P\<0.001. KIF3A, Kinesin Family Member 3A.

###### 

The expression level of KIF3A in 70 self-contrast patients.

                          Formal                           
  ----------------------- -------- ----- ----- ----- ----- ---------
  Intensity of positive                                    \<0.001
    Cancer                                                 
      0                   1          3     7     6   17    
      1                   0          5   11    10    26    
      2                   1          2     9   11    23    
      3                   0          0     2     2     4   
      No.                 2        10    29    29    70    
  Positive rate                                            \<0.001
    Cancer                                                 
      0                   1          3     8     4   16    
      1                   2          1     6     5   14    
      2                   0          5   18    14    37    
      3                   0          0     2     1     3   
      No.                 3          9   34    24    70    
  Final score                                              \<0.001
    Cancer                                                 
      0                   1          5     6     5   17    
      1                   2          7     6     9   24    
      2                   0          5   11    10    25    
      3                   0          0     2     1     3   
      No.                 3        17    25    25    70    

P\<0.001. KIF3A, Kinesin Family Member 3A.

###### 

Regular clinicopathological parameters of breast cancer.

  Characteristics         No.
  ----------------------- -------
  Age                     
    ≤53                     80
    \>53                    60
  Pathology grade         
    I                       12
    I--II                   21
    II                      95
    III                       7
  ER                      
    Positive                88
    Negative                42
  PR                      
    Positive                62
    Negative                51
  AR                      
    Positive              101
    Negative                40
  HER2                    
    Positive                42
    Negative                89
  Lymph node metastasis   
    TnN0                    86
    TnNn                    46
  P53                     
    Positive                86
    Negative                47
  Ki-67                   
    −                       24
    +                       75
    ++                      22
    +++                     10
  Ck56                    
    Positive                19
    Negative              112
  EGFR                    
    Positive                38
    Negative              102
  TN                      
    TNBC                    18
    NTNBC                 103

ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.

###### 

Relationship between KIF3A expression and clinicopathological parameters in the140 cases by intensity of positive.

                    Intensity of positive                            
  ----------------- ----------------------- ----- ----- ----- ------ ----------------------------------------------------
  Age                                                                0.728
    ≤53             2                       15    31    32      80   
    \>53            2                         7   25    26      60   
  Pathology grade                                                    0.000^[b](#tfn5-br-0-0-1061){ref-type="table-fn"}^
    I               1                         7     4     0     12   
    I--II           0                         2   12      8     22   
    II                2                     13    37    43      95   
    III               0                       0     2     5     7    
  ER                                                                 
    Positive        2                       12    35    39      88   0.463
    Negative        1                       10    16    15      42   
  PR                                                                 
    Positive        2                       10    32    34      78   0.475
    Negative        0                       11    20    20      51   
  AR                                                                 
    Positive        4                       12    36    48    100    0.021^[a](#tfn4-br-0-0-1061){ref-type="table-fn"}^
    Negative        0                       10    20    10      40   
  HER2                                                               
    Positive        1                         5   13    23      42   0.211
    Negative        2                       17    38    32      89   
  Lymph node                                                         
  metastasis                                                         
    TnN0            4                         4   23    37      86   0.013^[a](#tfn4-br-0-0-1061){ref-type="table-fn"}^
    TnNn            0                       18    21    16      46   
  P53                                                                
    Positive        1                       15    33    37      86   0.495
    Negative        2                         7   21    16      46   
  Ki-67                                                              
    −               1                         6   11      6     24   0.320
    +               2                       11    32    30      75   
    ++              0                         4     7   11      22   
    +++             0                         1     3     6     10   
  Ck56                                                               
    Positive        0                         2   10      7     19   0.757
    Negative        3                       20    43    46    112    
  EGFR                                                               
    Positive        4                       19    43    36    102    0.023^[a](#tfn4-br-0-0-1061){ref-type="table-fn"}^
    Negative        0                         3   13    21      37   
  TN                                                                 
    TNBC            0                         6     5     7     18   0.046
    NTNBC           6                       23    43    31    103    

P\<0.05

P\<0.001. KIF3A, Kinesin Family Member 3A; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.

###### 

Relationship between KIF3A expression and clinicopathological parameters in the140 cases by positive rate.

                          Positive rate                            
  ----------------------- --------------- ----- ----- ----- ------ ----------------------------------------------------
  Age                                                              0.358
    ≤53                   6               12    33    29    80     
    \>53                  2                 9   33    16    60     
  Pathology grade                                                  0.000^[b](#tfn7-br-0-0-1061){ref-type="table-fn"}^
    I                     3                 4     5     0     12   
    I--II                 0                 2   16      4     22   
    II                    4               15    40    36      95   
    III                   0                 0     4     3     7    
  ER                                                               0.031^[a](#tfn6-br-0-0-1061){ref-type="table-fn"}^
    Positive              5                 9   47    27      83   
    Negative              2               10    15    20      47   
  PR                                                               0.184
    Positive              3                 5   34    20      62   
    Negative              2               14    29    22      67   
  AR                                                               0.842
    Positive              7               12    48    33    100    
    Negative              1                 9   18    12      40   
  HER2                                                             0.579
    Positive              2                 5   18    17      42   
    Negative              5               14    45    25      89   
  Lymph node metastasis                                            0.135
    TnN0                  5                 5   23    21      54   
    TnNn                  3               16    42    23      84   
  P53                                                              0.184
    Positive              2               13    40    31      86   
    Negative              5                 7   22    12      46   
  Ki-67                                                            0.009^[a](#tfn6-br-0-0-1061){ref-type="table-fn"}^
    −                     2                 5   12      5     24   
    +                     4               11    39    21      75   
    ++                    1                 2     8   11      22   
    +++                   0                 1     3     6     10   
  Ck56                                                             0.873
    Positive              0                 3     9     7     19   
    Negative              7               16    53    36    112    
  EGFR                                                             0.109
    Positive              6               19    48    29    102    
    Negative              2                 2   18    15      37   
  TN                                                               0.657
    TNBC                  0                 4     8     6     18   
    NTNBC                 6               14    52    31    103    

P\<0.05

P\<0.001. KIF3A, Kinesin Family Member 3A; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.

###### 

Relationship between KIF3A expression and clinical pathological parameters in the140 cases by final score.

                          Final score                            
  ----------------------- ------------- ----- ----- ----- ------ ----------------------------------------------------
  Age                                                            0.465
    ≤53                   6             18    26    30      80   
    \>53                  2             14    26    18      60   
  Pathology grade                                                0.001^[a](#tfn8-br-0-0-1061){ref-type="table-fn"}^
    G I                   3               6     3     0     12   
    G I--II               0               4   13      5     22   
    G II                  4             21    32    38      95   
    G III                 0               1     3     3     7    
  ER                                                             0.008^[a](#tfn8-br-0-0-1061){ref-type="table-fn"}^
    Positive              5             15    39    24      83   
    Negative              2             15      9   21      47   
  PR                                                             0.135
    Positive              3             10    29    20      62   
    Negative              2             20    20    25      67   
  AR                                                             0.309
    Positive              7             19    37    37    100    
    Negative              1             13    15    11      40   
  HER2                                                           0.344
    Positive              2               7   14    19      42   
    Negative              5             23    35    26      89   
  Lymph node metastases                                          0.218^[a](#tfn8-br-0-0-1061){ref-type="table-fn"}^
    TnN0                  5               8   21    20      54   
    TnNn                  3             23    31    27      84   
  P53                                                            0.125
    Positive              2             22    29    33      86   
    Negative              5               9   19    13      46   
  Ki-67                                                          0.023^[a](#tfn8-br-0-0-1061){ref-type="table-fn"}^
    −                     2               6   10      6     24   
    +                     4             19    29    23      75   
    ++                    1               3     8   10      22   
    +++                   0               2     1     7     10   
  Ck56                                                           0.872
    Positive              0               4     8     7     19   
    Negative              7             26    40    39    112    
  EGFR                                                           0.054
    Positive              6             28    38    30    102    
    Negative              2               4   14    17      37   
  TN                                                             0.873
    TNBC                  0               3     8     7     18   
    NTNBC                 3             17    43    40    103    

P\<0.05

P\<0.001. KIF3A, Kinesin Family Member 3A; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.

###### 

Correlation of KIF3A expression and the survival rate of 140 breast cancer cases followed up to 2013.

  Item                    No.     P-value
  ----------------------- ------- -------------------------------------------------------
  Intensity of positive             0.047^[a](#tfn10-br-0-0-1061){ref-type="table-fn"}^
    Positive              136     
    Negative                  4   
  Positive rate                   0.628
    Positive              132     
    Negative                  8   
  Final score                     0.635
    Positive              132     
    Negative                  8   

P\<0.05. KIF3A, Kinesin Family Member 3A.

###### 

Correlation of KIF3A expression and the survival rate of 140 breast cancer cases followed up to 2014.

  Item                    No.   P-value
  ----------------------- ----- -----------------------------------------------------
  Intensity of positive         0.045^[a](#tfn11-br-0-0-1061){ref-type="table-fn"}^
    0                       4   
    1                     22    
    2                     56    
    3                     58    
  Positive rate                 0.217
    0                       8   
    1                     21    
    2                     66    
    3                     45    
  Final score                   0.223
    0                       8   
    1                     32    
    2                     52    
    3                     48    

P\<0.05. KIF3A, Kinesin Family Member 3A.
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